These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 8771497

  • 1. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
    Bonnefoy-Berard N, Revillard JP.
    J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
    [Abstract] [Full Text] [Related]

  • 2. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 3. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA.
    J Immunol; 1992 Jun 01; 148(11):3461-8. PubMed ID: 1534096
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1.
    Schwab R, Crow MK, Russo C, Weksler ME.
    J Immunol; 1985 Sep 01; 135(3):1714-8. PubMed ID: 3926880
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
    Cole MS, Anasetti C, Tso JY.
    J Immunol; 1997 Oct 01; 159(7):3613-21. PubMed ID: 9317161
    [Abstract] [Full Text] [Related]

  • 9. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
    Popma SH, Griswold DE, Li L.
    Int Immunopharmacol; 2005 Jan 01; 5(1):155-62. PubMed ID: 15589476
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
    Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM.
    J Immunol Methods; 2004 Feb 01; 285(1):111-27. PubMed ID: 14871540
    [Abstract] [Full Text] [Related]

  • 11. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
    Cole MS, Stellrecht KE, Shi JD, Homola M, Hsu DH, Anasetti C, Vasquez M, Tso JY.
    Transplantation; 1999 Aug 27; 68(4):563-71. PubMed ID: 10480417
    [Abstract] [Full Text] [Related]

  • 12. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlethwaite JR, Zivin RA, Jolliffe L, Bluestone JA.
    Transplantation; 1994 Jun 15; 57(11):1537-43. PubMed ID: 8009586
    [Abstract] [Full Text] [Related]

  • 13. OKT3-associated adverse reactions: mechanistic basis and therapeutic options.
    Suthanthiran M, Fotino M, Riggio RR, Cheigh JS, Stenzel KH.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):39-44. PubMed ID: 2530898
    [Abstract] [Full Text] [Related]

  • 14. Activation of human T lymphocytes II. Involvement of the T3 antigen in polyclonal T cell activation by mitogenic lectins and oxidation.
    Fleischer B.
    Eur J Immunol; 1984 Aug 15; 14(8):748-52. PubMed ID: 6332027
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins.
    Bonnefoy-Berard N, Verrier B, Vincent C, Revillard JP.
    Immunology; 1992 Sep 15; 77(1):61-7. PubMed ID: 1398765
    [Abstract] [Full Text] [Related]

  • 16. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
    Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS.
    Am J Kidney Dis; 1989 Nov 15; 14(5 Suppl 2):61-70. PubMed ID: 2479265
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
    Woods M, Guy R, Waldmann H, Glennie M, Alexander DR.
    Cell Immunol; 1998 May 01; 185(2):101-13. PubMed ID: 9636688
    [Abstract] [Full Text] [Related]

  • 19. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H.
    Cancer Res; 2001 Mar 01; 61(5):1976-82. PubMed ID: 11280755
    [Abstract] [Full Text] [Related]

  • 20. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
    Flamand V, Donckier V, Abramowicz D, Goldman M, Vandenabeele P, Urbain J, Moser M, Leo O.
    Cell Immunol; 1994 Aug 01; 157(1):239-48. PubMed ID: 8039247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.